Search

Leading the fight against Antimicrobial Resistance (AMR) in Western Australia.

Access to phage therapy, a treatment option for antibiotic resistant superbugs, is now one step closer for people with CF in WA thanks to a $500,000 donation from Conquer Cystic Fibrosis to the Wal-yan Respiratory Research Centre.

Wal-yan researchers have been awarded $500,000 for their innovative research, supported by the Western Australian Government’s Future Health Medical Research and Innovation (FHRI) Fund.

An exciting study is investigating whether a new therapeutic treatment for asthma will protect young sufferers from ongoing lung damage and improve their long-term health outcomes.

The Kids Research Institute Australia welcomes the Federal Government's stringent vaping reforms that took effect on 1 July 2024.

Nontypeable Haemophilus influenzae (NTHi) is a major otitis media (OM) pathogen, with colonization a prerequisite for disease development. Most acute OM is in children <5 years old, with recurrent and chronic OM impacting hearing and learning. Therapies to prevent NTHi colonization and/or disease are needed, especially for young children. Respiratory viruses are implicated in driving the development of bacterial OM in children.

Researchers from The Kids Research Institute Australia will share in almost $4 million in grants to continue groundbreaking research to tackle childhood cancer, asthma, respiratory viral infections and more.

Learn more about all of the Clinical Trials, Platforms & Cohorts at the Wal-yan respiratory centre.

Cystic fibrosis (CF) is the most common life‐shortening genetic disease affecting children.

On average, a person can expect to take more than 700 million breaths in their lifetime.